Allspring Global Investments Holdings LLC Sells 13,647 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Allspring Global Investments Holdings LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,474 shares of the biopharmaceutical company’s stock after selling 13,647 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Regeneron Pharmaceuticals were worth $31,085,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of REGN. Creative Planning lifted its position in Regeneron Pharmaceuticals by 22.7% in the 3rd quarter. Creative Planning now owns 11,793 shares of the biopharmaceutical company’s stock worth $12,397,000 after buying an additional 2,178 shares during the last quarter. Bfsg LLC lifted its position in Regeneron Pharmaceuticals by 3,352.0% in the third quarter. Bfsg LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $907,000 after purchasing an additional 838 shares during the last quarter. Good Life Advisors LLC lifted its position in Regeneron Pharmaceuticals by 60.0% in the third quarter. Good Life Advisors LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $404,000 after purchasing an additional 144 shares during the last quarter. Global Retirement Partners LLC lifted its position in Regeneron Pharmaceuticals by 44.1% in the third quarter. Global Retirement Partners LLC now owns 631 shares of the biopharmaceutical company’s stock valued at $663,000 after purchasing an additional 193 shares during the last quarter. Finally, Trifecta Capital Advisors LLC lifted its position in Regeneron Pharmaceuticals by 3.1% in the third quarter. Trifecta Capital Advisors LLC now owns 3,694 shares of the biopharmaceutical company’s stock valued at $3,883,000 after purchasing an additional 111 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.1 %

NASDAQ REGN opened at $673.60 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The stock has a market cap of $74.02 billion, a P/E ratio of 17.60, a P/E/G ratio of 2.38 and a beta of 0.08. The stock’s fifty day moving average price is $709.01 and its 200-day moving average price is $900.22. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the firm posted $11.86 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th.

Wall Street Analyst Weigh In

Several brokerages have weighed in on REGN. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Evercore ISI lowered their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Bank of America reiterated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Bernstein Bank lowered their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, TD Cowen lowered their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.